Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q5KZ
|
|||
| Former ID |
DNCL002566
|
|||
| Drug Name |
SGI110
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1] | |
| Company |
Astex Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C18H25N9NaO10P
|
|||
| Canonical SMILES |
[H-].C1C(C(OC1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)OC4CC(OC4CO)N5C=NC(=NC5=O)N)O.[Na+]
|
|||
| InChI |
1S/C18H24N9O10P.Na.H/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30;;/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30);;/q;+1;-1/t7?,8-,9+,10+,11?,12+;;/m0../s1
|
|||
| InChIKey |
AYXRQJHOBFJIHP-ZWBDGAAVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Target Info | Modulator | [2] |
| KEGG Pathway | Cysteine and methionine metabolism | |||
| Metabolic pathways | ||||
| MicroRNAs in cancer | ||||
| Pathwhiz Pathway | Methionine Metabolism | |||
| Pathway Interaction Database | Regulation of retinoblastoma protein | |||
| Reactome | PRC2 methylates histones and DNA | |||
| NoRC negatively regulates rRNA expression | ||||
| DNA methylation | ||||
| WikiPathways | Trans-sulfuration and one carbon metabolism | |||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Trans-sulfuration pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health. | |||
| REF 2 | Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.